![]() ![]() IWO - iShares Russell 2000 Growth ETF This fund is a listed as child fund of BlackRock Inc. Momentum Factor ETF ETF Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value JETSX - Total Stock Market Index Trust NAV SMXAX - SIIT Extended Market Index Fund - Class A and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value This representsĭWAS - Invesco DWA SmallCap Momentum ETF This fund is a listed as child fund of Invesco Ltd. The share price as of Septemis 15.75 / share. Schedule 13G indicates a passive investment of over 5%. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. ĤD Molecular Therapeutics Inc (NASDAQ:FDMT) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Viking Global Investors Lp, Bvf Inc/il, Ra Capital Management, L.p., VR Adviser, LLC, BlackRock Inc., Janus Henderson Group Plc, Deep Track Capital, LP, State Street Corp, Vanguard Group Inc, and Morgan Stanley. These institutions hold a total of 43,467,817 shares. ĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000E Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell 3000 Growth IndexĤD Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to Russell Microcap Growth IndexĤD Molecular Therapeutics, Inc.4D Molecular Therapeutics Inc (US:FDMT) hasĢ37 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). are subject to a Lock-Up Agreement Ending on. Ĭertain Common Stock of 4D Molecular Therapeutics, Inc. Ĭertain Options of 4D Molecular Therapeutics, Inc. Enter into License Agreement to Use 4Dmt's Proprietary Intravitreal R100 Vector for Rare Ophthalmic TargetsĬhardan Initiates 4D Molecular Therapeutics With Buy Rating, $30 Price TargetĬertain Warrants of 4D Molecular Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023ĤD Molecular Says Interim Data of 4D-150 Trial Shows Clinical Activity, Favorable Safety Profile in Wet Age-Related Macular Degeneration PatientsĤDMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 Prism Clinical Trial in Patients with Wet AMD at ASRS 2023ĤD Molecular Completes Enrollment of Phase 2 Trial in Patients with Wet Age-Related Macular DegenerationĬhardan Ups Price Target on 4D Molecular Therapeutics to $31 From $30, Maintains Buy RatingĤD Molecular Therapeutics Signs License Agreement With Potential Milestones-Linked Fee Options of up to $942.5 MillionĪstellas Pharma Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |